Overview

Pharmacokinetics and Preliminary Bioequivalence of Triferic (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients

Status:
Completed

Trial end date:
2016-07-01

Target enrollment:

Participant gender:

Summary

The main purpose is to determine the pharmacokinetics (PK) of Triferic iron administered via hemodialysate and via two different intravenous routes in adult patients with chronic kidney disease on chronic hemodialysis (CKD-5HD). It is an open-label, randomized single dose study.

Phase:

Phase 1

Details

Lead Sponsor:

Rockwell Medical Technologies, Inc.

Treatments:

Citric Acid
Hemodialysis Solutions
Iron